Drug Shortage Report for ACYCLOVIR SODIUM INJECTION
| Report ID | 215434 |
| Drug Identification Number | 02236926 |
| Brand name | ACYCLOVIR SODIUM INJECTION |
| Common or Proper name | ACYCLOVIR SODIUM INJECTION |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | ACYCLOVIR |
| Strength(s) | 50MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 20 mL |
| ATC code | J05AB |
| ATC description | DIRECT ACTING ANTIVIRALS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2023-12-15 |
| Actual start date | 2023-12-15 |
| Estimated end date | 2024-03-01 |
| Actual end date | 2024-01-29 |
| Shortage status | Resolved |
| Updated date | 2024-01-31 |
| Company comments | Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on our Acyclovir Sodium Injection 50 mg/mL SD Vial 20 mL effective December 15, 2023, until March 1, 2024. Effective December 1, 2023, allocations for our Acyclovir Sodium Injection 50 mg/mL SD Vial 10 mL will be increased to cover 100% of historical monthly demand of the 10 mL plus 100% of historical monthly demand of the 20 mL at a 2:1 ratio. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2024-01-31 | French | Compare |
| v3 | 2024-01-31 | English | Compare |
| v2 | 2024-01-09 | French | Compare |
| v1 | 2024-01-09 | English | Compare |
Showing 1 to 4 of 4